HoverAir Versa can be used like drone or like handheld gimbal pocket camera.
But what gets lost: its the first drone in long time that contains two native microphones!
So Versa is not only unique because its modular, its also the only modern DRONE with MIC!
Also 4k60, auto tracking, 10-bit H-LOG, 1/1.3 sensor, up to 17.5 stops dynamic range, 230g
TLDR: there are different kinds of Ebola. But it looks like old vaccines against previous Ebola kinds can somehow help even with the currect kind.
"These findings provide in vitro evidence that these Ebola vaccines induce cross-reactive antibody responses against BDBV. Although the possible protective value of these binding antibodies is unknown, EBOV glycoprotein-binding antibody levels have previously been associated with vaccine-induced protection. Our findings are consistent with those in studies involving nonhuman primates that showed partial heterologous protection after EBOV vaccination. In the absence of a BDBV-specific vaccine, these data support the evaluation of readily available Ebola vaccines during the current outbreak. The single-dose rVSV vaccine, which induced BDBV-binding antibody responses at 28 days and is currently available through the global Ebola vaccine stockpile, represents an immediately deployable candidate that could be evaluated during the ongoing outbreak."
"BCG vaccination against TB may also reduce malaria incidence through non-specific innate immune activation.
We investigated whether giving BCG alongside an adenoviral-vectored malaria vaccine improves protection against malaria in mice.
Co-immunisation broadened and strengthened the early innate cytokine responses, enabling strong CD8^(+) T cell-dependent protection.
Our findings suggest co-immunisation with BCG and adenoviral vector as a promising strategy to combat both TB and malaria in double-endemic regions."
Prove me otherwise
TLDR: with this new adjuvant, we created nasal vaccine that gave rodents and apes immunity against all coronaviruses, stoping viruses even before infection, it can be good for nasal flu vaccines too.
"A major barrier in mucosal vaccine development is achieving localized immunity without systemic toxicity.
Here we engineered NanoCF501, a nanoparticulate STING agonist formulated with a 2-ethyl-2-oxazoline polymer. As an adjuvant, NanoCF501 facilitates efficient mucus penetration and localized respiratory retention, minimizing systemic exposure as confirmed by pharmacokinetics in rats.
In mice, intranasal co-administration of NanoCF501 (1/20th the systemic dose) with an antigen comprising multivalent fragments derived from different coronaviruses induced robust mucosal and systemic immunity, conferring protection against homologous/heterologous pan-β-coronaviruses. Single-cell transcriptomics reveals STING-dependent reprogramming of lung antigen-presenting cells, enhancing adaptive responses.
Our results were further validated in non-human primates and were extended to licensed influenza vaccines, showing that NanoCF501 can be used to repurpose intramuscular antigens for mucosal delivery.
By integrating nanoscale rational design with innate targeting, NanoCF501 establishes a universal adjuvant for next-generation vaccines, advancing nanomedicine for pandemic preparedness."
TLDR: new flu vaccine from Moderna, mRNA-1010, gives you broader protection against influenza strains than previous vaccines, its more close to the dream of "universal flu vaccine"
With similar tech, some people will maybe not need new flu shot every year
"Adjuvanted vaccines are considered interventions that not only enhance pathogen-specific immune responses but also influence non-specific effects.
Epidemiological data across various respiratory pathogens indicate that vaccination in older adults has benefits that go beyond simply preventing infections and their direct complications.
For instance, influenza vaccination in this demographic has been linked to decreased risks of cardiovascular events, reduced progression of frailty, and less disability. These outcomes might not solely be attributed to lower infection rates but could also involve immune-modulating mechanisms. While even standard inactivated influenza vaccines demonstrate these effects, they appear more pronounced with enhanced versions of influenza vaccines.
Respiratory syncytial virus (RSV) vaccines significantly reduce hospitalization rates and severe outcomes in older adults as well. This population is particularly vulnerable to cascading health declines triggered by respiratory infections, such as worsening chronic conditions, functional deterioration, and prolonged recovery periods.
Emerging research has also shed light on unexpected benefits of vaccination in reducing dementia risk. Studies suggest a possible link between herpes zoster vaccination and lower dementia rates, with a stronger effect observed in recombinant zoster vaccine (RZV) formulated with the AS01 adjuvant. A similar, albeit less prominent, association has been noted for the AS01E-adjuvanted RSV vaccine.
While the mechanisms behind these observations remain unclear, these trends hint at the possibility of adjuvants acting beyond mere infection prevention, perhaps through broader immune system modulation.
These findings collectively suggest that vaccination might play a role in boosting physiological resilience independent of antigen-specific effects.
One explanatory concept is "trained immunity," which refers to the ability of innate immune cells—like monocytes, macrophages, and natural killer cells—to undergo functional and metabolic reprogramming after an initial stimulus. This reprogramming involves long-lasting epigenetic changes that enhance their responsiveness to future challenges.
Although much of the evidence for trained immunity stems from live-attenuated vaccines like BCG, which are known to provide cross-protection against various unrelated pathogens, its occurrence in older adults following vaccination still requires deeper investigation. Evidence for similar reprogramming with non-live vaccines or specific adjuvants exists but remains limited and depends heavily on the context.
Some studies have found that adjuvants like MF59 and AS03 can induce sustained immune reprogramming consistent with trained immunity characteristics. However, there is a lack of direct evidence linking these effects to tangible aging-related clinical benefits.
Whether adjuvants contribute to improved health outcomes among older adults through trained immunity, better coordination between innate and adaptive responses, or by helping regulate baseline inflammation levels remains an open area for further exploration."
"Highly attenuated poxviruses serve as potent viral vectors, oncolytic agents, and therapeutic vaccines. They can accommodate and stably maintain a large genomic payload of foreign inserts. Their limited replication in human cells provides an excellent safety profile, but it concomitantly necessitates higher doses of infectious particles for full therapeutic efficacy.
We review recent advances in bioprocesses for the pharmaceutical production of poxvirus-based vectors, focusing mainly on the vaccinia virus and the Orf virus. These include upstream processing using highly permissive cell substrates, optimized feeding strategies, and a virus phenotype that facilitates downstream processing. The study explores ongoing challenges and identifies strategies to adapt the downstream process to intensified upstream processes in order to achieve an economic end-to-end production.
For notably increased virus yields of up to 2 log after amplification, we propose to replace classic adsorption chromatography by a collective and continuous purification platform for separating the virus from process-related impurities. Filtration operations facilitate process scalability while reducing volumes, which is beneficial for a flow-through polishing to meet pharmaceutical quality attributes.
Combined with artificial intelligence modeling, these advancements alleviate financial pressures on healthcare systems and accelerate the production of novel vaccine candidates for clinical use."
"We designed and preclinically tested two mRNA–lipid-nanoparticle-based vaccine candidates to protect against tuberculosis.
BNT164a1 and BNT164b1 encode the same eight Mycobacterium tuberculosis antigens expressed across different infection stages: Ag85A, Hrp1, ESAT-6, RpfD, RpfA, HbhA, M72 and VapB47.
BNT164a1 utilizes nucleoside-unmodified mRNA, whereas BNT164b1 utilizes N^(1)-methylpseudouridine-modified mRNA.
Prime-boost immunization with BNT164 candidates elicited antibody and/or T cell responses against all antigens in three mouse strains (C57BL/6, BALB/c and HLA-A2.1/DR1 humanized mice).
The candidates demonstrated favorable safety profiles in a rat toxicity study and significantly reduced bacterial burdens of two M. tuberculosis strains in murine aerosol challenge models.
BNT164 protection was correlated with granuloma infiltration by CD8^(+) T cells with memory precursor phenotypes.
In conclusion, BNT164a1 and BNT164b1 were immunogenic, well tolerated and efficacious in preclinical models and have entered phase 1/2 clinical trials (NCT05537038, NCT05547464)."
Article published: 12 June 2026
"Human vaccine responses vary widely, but the determinants remain incompletely defined.
Here we analyzed 66 cytokines across four inactivated influenza vaccine (IIV) cohorts over five seasons (n = 581) and identified baseline serum interleukin (IL)-18 and interferon (IFN)-β as correlates of day 28 antibody responses. To test causality, we evaluated 19 cytokines in human tonsil and spleen organoids and found that type I IFNs, IL-21 and IL-12, but not IL-18 or IFNγ, enhanced antibody production.
The addition of IFNβ to IIV recapitulated key features of the live-vaccine cytokine program. IL-12 and IL-21 defined a parallel pathway independent of type I IFNs, with IL-12 inducing IL-21 in humans, unlike in mice. Delivery of IL-21 or IFNβ via mRNA lipid nanoparticles in vivo promoted long-lived plasma cell formation.
Together, these findings define parallel pathways that regulate vaccine immunity. Our approach unites high-throughput organoid testing and human cohort studies, establishing a human-centric platform to identify adjuvant candidates."
This study again shows that if you get covid-19 vaccine and suplement enough D3, you have lower chance of catching covid than just vaccinated people.
We expected this from around 2020. I always keep my D3 status high and especially days before vaccination I suplement it a lot.
If your country has dark winters, do like 5000 IU of D3K2 drops under your tongue after your first fatty meal (after breakfast or after lunch).
I love this one for three reasons:
BCG reduced insulin use for people with type 1 diabetes and another autoimmune condition.
I even know guys buying these from the internet and shooting them themselves against herpes too
TLDR: there is open access adjuvant that makes vaccines stronger. Pure recombinant protein vaccines are usually weak, but with this adjuvant, COVAC-2 was tested as a good covid-19 booster. This can be good stable vaccine for poor countries.
"This Phase 1 clinical trial evaluated the safety and immunogenicity of COVAC-2, a recombinant protein subunit vaccine as a heterologous booster in adults previously immunized with authorized COVID-19 vaccines (NCT05226702).
COVAC-2 contains the SARS-CoV-2 S1 spike protein subunit adjuvanted with Sepivac SWE™, an open-access oil-in-water adjuvant.
Sixty participants were randomized to receive a single intramuscular dose of COVAC-2 (10 µg or 25 µg) or placebo, with follow-up through Day 180.
The vaccine was well tolerated, with most adverse events being mild or moderate; no serious adverse events were attributed to vaccination.
Immunogenicity assessments included spike-binding antibody ELISA, pseudovirus neutralization assays (PNA), ELISpot, and flow cytometry.
The 25 µg dose elicited the strongest humoral and cellular responses, with peak antibody titers observed 14 d after COVAC-2 vaccination. While titers waned, they were sustained above baseline through Day 180.
ELISpot and flow cytometry revealed elevated IFN-γ and IL-2 responses indicating antigen-specific T-cell activation. Minimal IL-4 and IL-13 responses were demonstrated by flow cytometry.
These findings support the safety and immunogenicity of COVAC-2 as a heterologous booster, particularly at the 25 µg dose level. The favorable safety profile, induction of immune responses, and thermal stability of the vaccine formulation suggest its potential utility in global vaccination strategies, especially in low- and middle-income countries. COVAC-2 may offer a scalable and accessible platform for enhancing protection against COVID-19."
For people not watching the situation, this will be very unexpected AR player.
After buying Forcite camera helmets in 2024 and colaborating with luxury motorcycle helmet manufacturer AVG from 2025 (like Meta with Ray-ban), GoPro wants to start selling their helmets with integrated camera at fall 2026 (before Christmas).
GoPro also wants to sell licenses to other sport companies.
Dont also forget that GoPro has Max 2, maybe the best looking consumer 360 camera when there is enough light (in lowish light you need Insta360 X5 or DJI Osmo 360). So VR / XR is not of the table for GoPro too.
TLDR: MenB vaccine also gives some bonus protection against gonorrhoea. Today these scientist published positive results for their specific Gonococcal vaccine. It makes sense to them to start testing something similar on humans.
"Neisseria gonorrhoeae causes 82 million global cases of gonorrhoea annually.
Multidrug-resistant gonococci threaten to make gonorrhoea untreatable.
Meningococcal vaccines MeNZB and 4CMenB (Bexsero), containing Neisseria meningitidis group B detergent-extracted outer membrane vesicles (dOMV), cross-protect against gonorrhoea with 31–59% effectiveness.
We hypothesised that gonococcal OMV-based vaccines would have greater efficacy against gonorrhoea than meningococcal vaccines. We developed native OMV (nOMV) candidate Neisseria vaccines from gonococcal strains GC_0817560 and FA1090, and meningococcal B strain NZ98/254. lpxL1 and rmp genes were deleted to reduce reactogenicity and minimise induction of unprotective or blocking antibodies. nOMV were characterised and formulated with aluminium hydroxide.
Deletion of lpxL1 markedly reduced nOMV-induced IL-6 release from peripheral blood mononuclear cells. nOMV derived from GC_0817560lpxL1^(−)rmp^(−) and FA1090lpxL1^(−)rmp^(−) induced greater quantities of gonococcal-specific serum IgG and accelerated clearance of FA1090 from oestradiol-treated BALB/c mice significantly faster than 4CMenB and NZ98/254lpxL1^(−)rmp^(−) nOMV (P < 0.0001).
Gonococcal nOMV-based vaccines represent promising candidates for further development."
The field of EBV vaccine development is at an inflection point.
Spurred by the definitive causal link between EBV and MS, researchers have converged on sophisticated, multi-antigen strategies designed to overcome the failures of the past. This consensus on what antigens to target has been coupled with a vibrant divergence of competing, next-generation technology platforms—including mRNA, nanoparticles, VLPs, and novel viral vectors—creating a dynamic and highly competitive research landscape.
Populations previously exposed to EBV should be vaccinated for three primary reasons:
It was proven many times that vaccine against shingles steers off dementia, but why?
"Three non-mutually exclusive pathways merit direct evaluation:
TLDR: maybe varicella zoster speeds up dementia, maybe vaccines positivelly modulate your imunity even though you never meet the virus.
"Toxoplasma gondii is an infectious disease that infects nearly one third of the world’s population and endangers the health of immunocompromised people, pregnant women, and livestock. There are no existing drugs able to treat the infection and prevent tissue cysts from developing. Therefore, the creation of a safe vaccine should be considered as a matter of great importance.
While many of the vaccines have not proven successful in the past, recently created live-attenuated vaccines (LAVs) using CRISPR–Cas9 gene editing technology were able to outperform the previous ones.
The current review aims to highlight the recent progress in genetically engineered LAVs against T. gondii. In particular, the knockout strains affecting metabolic genes (ompdc, uprt, and adsl), virulence genes (rop18), and host–parasite interactions (gra5, gra72, had2a, and cdpk3) will be mentioned. LAVs described above demonstrate high attenuating effects and ability to protect mice by inducing immunity on the basis of specific IgG (IgG2a), IFN-γ, IL-12, and CD4^(+), CD8^(+) T cells.
Furthermore, vaccination provides protection from a lethal infection caused by types I, II, and Chinese 1 strains of T. gondii as well as preventing development of tissue cysts in chronic infection. RHΔompdcΔuprt is an example of an LAV that can be used to reduce oocyst shedding in cats and promote the One Health concept.
In general terms, genetically engineered LAVs can effectively deal with toxoplasmosis infection with better attenuation immunogenicity balance than other vaccines."
"Advances in gene-editing technologies, including CRISPR-Cas9 have shifted the paradigm of T. gondii vaccine development. Instead of broad methods, removal of specific genes tied to survival or control has led to live forms that trigger stronger immunity in early tests.
Unlike older types, these altered versions - PruΔgra72, WH3Δrop18, RHΔompdcΔuprt - persist just enough to train the immune system without causing illness. Because they provoke long-lasting defense skewed toward Th1 activity, protection emerges across multiple stages of infection.
Evidence suggests such strains may limit both sudden outbreaks and lingering infections while lowering cyst presence in tissues. With disruption of spread now within reach, blocking transmission becomes more than theoretical. Despite unresolved issues in safety, production, and regulation, progress toward a working toxoplasmosis vaccine has never been on firmer ground.
New genetic markers keep emerging - each discovery shaping better approaches to disable multiple genes at once. Testing across relevant animals confirms which versions hold real promise. As awareness moves towards the ecological and health implications, there is currently an effort by scientists to design a system that would effectively prevent this disease from spreading. The way forward will not hinge on groundbreaking discoveries but rather on the seamless integration of biology, veterinary medicine, and public health concerns."
In this Phase 1 / 2 trial, GlaxoSmithKline wants to test 16 different vaccine formulations against placebo on 1808 people (so over 100 people will get each one).
Half against human respiratory syncytial virus and human metapneumovirus together, half against hMPV only (as RSV vaccines like Pfizer's Abrysvo already exist).
Like this, GSK can find the best formulation and later start Phase 3 with it.